9-Methyl-β-carboline

Name: 9-Methyl-β-carboline
Brand: MedChemExpress
SKU: HY-W049881
Rating: 4.5 (0 reviews)

製品番号: HY-W049881 純度: 99.86%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

9-Methyl-β-carboline is a monoamine oxidase inhibitor and dopaminergic modulator, with an IC₅₀ of 1 μM against human MAO-A and an IC₅₀ of 15.5 μM against human MAO-B. 9-Methyl-β-carboline possesses cognitive enhancement potential and can cross the blood-brain barrier. 9-Methyl-β-carboline increases dopamine levels by inhibiting monoamine oxidase activity and microglial proliferation. 9-Methyl-β-carboline activates PKA/PKC and mitochondrial respiratory chain complex I, promotes neurotrophic factor expression and reduces α-synuclein (α-synuclein) levels, thereby reversing neurotoxin-induced dopaminergic neuron damage. 9-Methyl-β-carboline also regulates the PI3K pathway and exerts an anti-proliferative effect on astrocytes. 9-Methyl-β-carboline is widely used in Parkinson's disease-related studies.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

9-Methyl-β-carboline 構造式

CAS 番号 : 2521-07-5

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 27	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 27	在庫あり	Estimated Time of Arrival: December 31
Solid
500 mg	$25	在庫あり	Estimated Time of Arrival: December 31
1 g		お問い合わせ
5 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Dopamine Receptor アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Dopamine Receptor D₁ Receptor D₂ Receptor D₃ Receptor D₄ Receptor D₅ Receptor

PI3K アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

Monoamine Oxidase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

MAO-A MAO-B

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

hMAO-A

1 μM (IC₅₀)

hMAO-B

15.5 μM (IC₅₀)

体外実験

9-Methyl-β-carboline increases the number of dopaminergic neurons and promotes neurite branching in primary midbrain cultures^[1].
9-Methyl-β-carboline (90 μM; 48 h) is taken up by primary dopaminergic neurons via DAT, and increases the number of THir neurons by 30% (peak at 90 μM for 48 h) by upregulating TH expression in pre-existing non-proliferative DDCir neurons; this effect is partially reversible after drug withdrawal and depends on the PKA/C signaling pathway^[2].
9-Methyl-β-carboline (10-150 μM; 48 h) exerts a concentration-dependent antiproliferative effect on primary mouse cortical astrocytes^[4].
9-Methyl-β-carboline (90 μM; 48 h) significantly upregulates the expression of multiple neurotrophic factors and related genes in primary mouse cortical astrocyte cultures^[4].
The stimulatory effect of 9-Methyl-β-carboline (90 μM; 48 h) on the number of tyrosine hydroxylase-immunoreactive dopaminergic neurons in primary mouse midbrain cell cultures is mediated by the phosphatidylinositol 3-kinase (PI3K) pathway^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[4]

Cell Line:	Primary murine cortical astrocytes
Concentration:	10 μM, 30 μM and 50 μM
Incubation Time:	48 h
Result:	Exerted anti-proliferative effects on primary murine cortical astrocytes in a concentration-dependent manner, reducing BrdU incorporation by 39 ± 4% at 90 μM and 71 ± 6% at 150 μM for 48 h.

体内実験

9-Methyl-β-carboline (2 μmol/100 g body weight; i.p.; daily; 10 days) improves hippocampus-dependent spatial learning in female Wistar rats, associated with a significant increase in hippocampal dopamine levels and enhanced dendritic and synaptic proliferation in dentate gyrus granule neurons, while 9-Methyl-β-carboline (2 μmol/100 g body weight; i.p.; daily; 5 days) shows no significant PD effects^[1].
9-Methyl-β-carboline (0.48 μmol/kg) restores the number of THir neurons in the SN pars compacta of MPP⁺-treated rats, upregulates neurotrophic factor expression, and enhances mitochondrial complex I activity^[2].
9-Methyl-β-carboline (0.105 mg/kg/day; intracerebroventricular; continuous infusion; 14 days) exerts restorative effects in a rat model of Parkinson’s disease, normalizing striatal dopamine levels and THir cell counts in the SNc, increasing mitochondrial complex I activity by ~80%, and strongly upregulating neurotrophin gene and protein expression^[3].
9-Methyl-β-carboline exerts neuroregenerative effects in an MPP⁺-induced rat model of Parkinson's disease and increases expression of key neurotrophic factors^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar (female, 7 weeks old at study start)^[1]
Dosage:	2 μmol/100 g body weight (10-day treatment: spatial learning, dopamine levels, dendritic/synaptic changes); 2 μmol/100 g body weight (5-day treatment: no significant effects)
Administration:	i.p.; daily; 5 days followed by 5 days vehicle; daily; 10 days
Result:	Reduced spatial learning errors in radial maze, with rats reaching ≤1 error criterion after 7 training trials; confirmed significant treatment effect on test acquisition with significant differences vs. controls from trial 7 onward (10-day treatment only). Significantly increased hippocampal dopamine levels to ~14 ng/g wet weight, with significant elevations vs. non-injected and vehicle-treated rats (10-day treatment only). Significantly increased dendritic length of dentate gyrus granule neurons at 60 μm, 110 μm, and 160 μm from the soma (10-day treatment only). Significantly increased total dendritic spine number per tree at 60 μm, 110 μm, and 160 μm from the soma (10-day treatment only). Significantly increased dendritic complexity (number of dendritic intersections) at 110 μm from the soma (10-day treatment only). Showed no significant difference from controls in spatial learning, no significant hippocampal dopamine elevation, and no significant dendritic/synaptic changes (5-day treatment only).

分子量

182.22

分子式

C₁₂H₁₀N₂

CAS 番号

2521-07-5

Appearance

Solid

Color

Off-white to light yellow

SMILES

CN1C2=C(C=CC=C2)C3=C1C=NC=C3

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Store at room temperature 3 years

*In solvent : -80°C, 6 months; -20°C, 1 month (Store at room temperature 3 years)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (548.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.4879 mL	27.4394 mL	54.8787 mL
5 mM	1.0976 mL	5.4879 mL	10.9757 mL
10 mM	0.5488 mL	2.7439 mL	5.4879 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (27.44 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (27.44 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.86%

Select Batch:

データシート (285 KB) SDS (393 KB)

COA (254 KB) HNMR (131 KB) RP-HPLC (228 KB) MS (68 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Gruss M, et al. 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. J Neurochem. 2012;121(6):924-931. [Content Brief]

[2]. Polanski W, et al. Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?. Expert Rev Neurother. 2011;11(6):845-860. [Content Brief]

[3]. Wernicke C, et al. 9-Methyl-beta-carboline has restorative effects in an animal model of Parkinson's disease. Pharmacol Rep. 2010;62(1):35-53. [Content Brief]

[4]. Keller S, et al. 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes. J Neural Transm (Vienna). 2020;127(7):999-1012. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.4879 mL	27.4394 mL	54.8787 mL	137.1968 mL
	5 mM	1.0976 mL	5.4879 mL	10.9757 mL	27.4394 mL
	10 mM	0.5488 mL	2.7439 mL	5.4879 mL	13.7197 mL
	15 mM	0.3659 mL	1.8293 mL	3.6586 mL	9.1465 mL
	20 mM	0.2744 mL	1.3720 mL	2.7439 mL	6.8598 mL
	25 mM	0.2195 mL	1.0976 mL	2.1951 mL	5.4879 mL
	30 mM	0.1829 mL	0.9146 mL	1.8293 mL	4.5732 mL
	40 mM	0.1372 mL	0.6860 mL	1.3720 mL	3.4299 mL
	50 mM	0.1098 mL	0.5488 mL	1.0976 mL	2.7439 mL
	60 mM	0.0915 mL	0.4573 mL	0.9146 mL	2.2866 mL
	80 mM	0.0686 mL	0.3430 mL	0.6860 mL	1.7150 mL
	100 mM	0.0549 mL	0.2744 mL	0.5488 mL	1.3720 mL